With Hong Kong’s Listing Rules now welcoming pre-revenue biotech companies, HKEX has been active sharing success stories and the listing process with potential biotech issuers around the world. Today, HKEX joined the China Healthcare Investment Conference in Shanghai to talk about biotech opportunities in Hong Kong.
HKEX introduced new Listing Rules last April to welcome pre-revenue biotech and life sciences companies. Since then, six pre-revenue biotech companies have debuted in Hong Kong, with the seventh company set to bang the IPO gong tomorrow morning.
HKEX Head of China Issuer Services Silvia Chen delivered the keynote speech in Shanghai, mentioning that around ten biotech companies have filed applications to list in Hong Kong from a range of businesses including bio-macromolecule pharmaceuticals, small molecule pharmaceuticals, medical devices, and other sub-sectors of the biotech sector.
Chen also said HKEX is a key platform to connect companies, scientists and investors to support the development of the biotechnology industry.
Earlier this week, HKEX Senior Vice President Michael Chan spoke to a delegation of Australian life sciences companies on Tuesday on the opportunities available to companies that list in Hong Kong.